Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 5/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.30 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.30 |
| ▸ | USP14 | P54578 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1187327 | 0.91 | ALDH1A1 (0.38) | ALDH1A1GLAABCB1CETPGPR35 | |
| SCHEMBL1175089 | 0.85 | CYP4F2 (0.41) | ALDH1A1GLAGPR35CYP2C9CYP2C19 | |
| SCHEMBL1174838 | 0.81 | NPSR1 (0.46) | ALDH1A1GLAFFAR1FFAR4 | |
| SCHEMBL3211949 | 0.79 | ALDH1A1 (0.35) | ALDH1A1HDAC8CYP2C9STING1 | |
| SCHEMBL3216676 | 0.78 | TSHR (0.33) | STING1 | |
| SCHEMBL21473717 | 0.75 | PDE3B (0.45) | ALDH1A1GPR35CYP2C9 | |
| SCHEMBL6832152 | 0.74 | GPR35 (0.38) | ALDH1A1GLAGPR35CYP2C9CYP2C19 | |
| SCHEMBL1188112 | 0.74 | MTNR1A (0.30) | — | |
| SCHEMBL22014712 | 0.73 | ALDH1A1 (0.34) | ALDH1A1GLAABCB1GPR35 | |
| SCHEMBL6593052 | 0.72 | RXRA (0.36) | GPR35CYP2C19FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580824-B2 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-12 | — | — | US | disclosed |
| EP-2069335-B1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| EP-2069336-B1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-8288554-B2 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-2069335-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| EP-2069336-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008029371-A1 | PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063108-A1 | Pyridin-4-yl derivatives as immunomodulating agents | CD4, FCGRT, IL2 | ALDH1A1 891/4885GLA 2087/4885ABCB1 1789/4885 |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | CD4, FCGRT, CD47 | ALDH1A1 1077/4885GLA 1554/4885ABCB1 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.